ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spooner, C
Right arrow Articles by Saunders, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spooner, C
Right arrow Articles by Saunders, L.
Eur Respir J 2000; 16: 30-37
Copyright © ERS Journals Ltd 2000

Original Articles

Nedocromil sodium in the treatment of exercise-induced asthma: a meta-analysis

C Spooner, BH Rowe, and LD Saunders

Exercise-induced asthma (or bronchoconstriction) afflicts millions of people worldwide. While generally self-limiting, it can hinder performance and reduce activity levels, thus it is an important condition to diagnose and treat. The objective of this review was to assess the prophylactic effect of a single dose of nedocromil sodium on exercise-induced asthma. The Cochrane Airways Group trials register, the Cochrane Controlled Trials Register, Current Contents, reference lists of relevant articles, review articles and textbooks were searched for randomized trials comparing a single dose of nedocromil to placebo to prevent exercise-induced asthma in people >6 yrs of age. Authors and the drug manufacturer were contacted for additional trials. Trial quality assessments and data extraction were conducted independently by two reviewers. Authors were contacted when possible. Twenty trials were included. All were rated as having good methodological quality. Nedocromil inhibited bronchoconstriction in all age groups. The pooled weighted mean difference for the maximum percentage fall in forced expiratory volume in one second was 15.6%, (95% confidence interval (95% CI): 13.2-18.1) and for the peak expiratory flow was 15.0% (95% CI: 8.3-21.6). These differences are both statistically and clinically significant. After nedocromil the time to recover normal lung function was <10 min compared to >30 min with placebo. Nedocromil had a greater effect on people with a fall in lung function of >30% from baseline. There were no significant adverse effects reported with this short-term use. In conclusion, Nedocromil taken before exercise appears to reduce the severity and duration of exercise-induced bronchoconstriction. This effect appears to be more pronounced as severity increases.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
E. K. Chu and J. M. Drazen
Asthma: One Hundred Years of Treatment and Onward
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1202 - 1208.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
T. J. Wetter, Z. Xiang, D. A. Sonetti, H. C. Haverkamp, A. J. Rice, A. A. Abbasi, K. C. Meyer, and J. A. Dempsey
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes
J Appl Physiol, July 1, 2002; 93(1): 116 - 126.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G LASZLO, P J HELMS, M J A TASCHE, J H J M UIJEN, R M D BERNSEN, J C DE JONGSTE, and J C VAN DER WOUDEN
Time to consign cromoglycate to history?
Thorax, June 1, 2001; 56(6): 501a - 501.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. D. BRANNAN, S. D. ANDERSON, K. GOMES, G. G. KING, H. KIM CHAN, and J. PAUL SEALE
Fexofenadine Decreases Sensitivity to and Montelukast Improves Recovery from Inhaled Mannitol
Am. J. Respir. Crit. Care Med., May 1, 2001; 163(6): 1420 - 1425.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the European Respiratory Society.